Scott Wright, M.D., Mayo Clinic, presenting the results at ACC on the two-dose a year LDL-lowering drug inclisiran, which had a significant reduction in LDL in the ORION Trial. #ACC20 #ACC2020

Scott Wright, M.D., Mayo Clinic, presenting the results at ACC on the two-dose a year LDL-lowering drug inclisiran, which had a significant reduction in LDL in the ORION Trial.

News | Pharmaceuticals | March 28, 2020 | Dave Fornell, Editor

March 28. 2020 — Among adults with heterozygous familial hypercholesterolemia, those who received the drug...

Find more news from ACC 2020.Women carry heavier burden of chest pain, but less artery narrowing according to data in a substudy of the ISCHEMIA Trial. #ACC20 #ACC2020 #ISCHEMIA

Women carry heavier burden of chest pain, but less artery narrowing, according to data in a substudy from the ISCHEMIA Trial. 
 

News | Womens Cardiovascular Health | March 28, 2020

March 28, 2020 — Women with coronary artery disease that reduces blood flow and oxygen to the heart muscle (ischemia...

Dapagliflozin Reduces Heart Failure Worsening and Death in DAPA-HF Sub-analysis. #ACC20 #ACC2020
News | Heart Failure | March 28, 2020

March 28, 2020 — New data from a sub-analysis of the landmark Phase III...

Naveen Pereira, M.D., co-principal investigator of the TAILOR-PCI study, explaining the conclusions of the late-breaking trial data during the virtual ACC20 meeting. #ACC20 #ACC2020

Naveen Pereira, M.D., co-principal investigator of the TAILOR-PCI study, explaining the conclusions of the late-breaking trial data during the virtual ACC20 meeting. 

News | Antiplatelet and Anticoagulation Therapies | March 28, 2020

March 28, 2020 — The TAILOR-PCI trial that used genetic testing to guide which antiplatelet medication was given to...

The VOYAGER PAD trial showed patients with symptomatic peripheral artery disease (PAD) who took the blood thinner rivaroxaban with aspirin after undergoing a procedure to treat blocked arteries in the leg had a 15 percent reduction in the risk of major adverse limb and cardiovascular events when compared with those receiving aspirin alone. #ACC20

The VOYAGER PAD trial showed patients with symptomatic peripheral artery disease (PAD) who took the blood thinner rivaroxaban with aspirin after undergoing a procedure to treat blocked arteries in the leg had a 15 percent reduction in the risk of major adverse limb and cardiovascular events when compared with those receiving aspirin alone.

News | Peripheral Artery Disease (PAD) | March 28, 2020

March 28, 2020 — People with symptomatic...

Italian Cardiologist Maurizio Galderisi Died From COVID-19, #coronavirus #COVID19
News | Coronavirus (COVID-19) | March 27, 2020

March 27, 2020 — In Italy today, novel coronavirus (COVID-19) claimed the life of well known cardiologist...

The heart team at St. James University Hospital Dublin was the first to perform a human implant of the CroiValve Duo Tricuspid Coaptation Valve technology for tricuspid repair.  

The heart team at St. James University Hospital Dublin was the first to perform a human implant of the CroiValve Duo Tricuspid Coaptation Valve technology for tricuspid repair.  

News | Heart Valve Technology | March 25, 2020

 

March 25, 2020 — CroiValve announced the successful first human use of its Duo Tricuspid Coaptation Valve...

News | Coronavirus (COVID-19) | March 25, 2020 | Dave Fornell, Editor

March 25, 2020 — The U.S. Food and Drug Administration (FDA) said it is taking action to increase U.S. supplies of...

Hydroxychloroquine causes prolonged QT intervals and cardiac arrhythmias, so this needs to be considered in patients being treated with this drug for COVID-19. #COVID19 #SARScov2 #coronavirus

Hydroxychloroquine causes prolonged QT intervals and cardiac arrhythmias, so this needs to be considered in patients being treated with this drug for COVID-19.

Feature | Coronavirus (COVID-19) | March 24, 2020 | Marianne Pop, Pharm.D, BCPS

It has been more than three months since the word coronavirus was uttered on everyone’s lips and all over the social...

Overlay Init